Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

REVEALED: 2 - The Real Truth

Shot in the arm for GSK and AstraZeneca from cancer drug sales

The blue chip drug makers saw first quarter earnings beat market expectations.

Evening Standard

Mandelson’s lobbying firm Global Counsel went bust owing £4.6m, report says

Consultancy that advised TikTok, Palantir and GSK collapsed amid fallout over former minister’s links to Jeffrey Epstein

The Guardian - UK

GSK reports promising early results in ovarian and womb cancer drug trial

Mo-Rez reduced or eliminated tumours in over 60% of patients and is expected to be a blockbuster drug

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Bargain-Cheap Small Caps Worth a Second Look

Three low P/E small-cap stocks offer distinct catalysts and upside potential as investors look ahead to a broader market rally

MarketBeat

He knows the pain of Lyme disease better than anyone, but RFK Jr. is about to make a decision that has health experts terrified

Here’s some big news in the fight against Lyme disease: Pfizer just announced its plan to file for regulatory approval of a new Lyme disease vaccine. If it gets the green light, this would be the first vaccine for the tick-borne illness available in over two decades. This new development,…

The Mary Sue

Antimicrobial resistance is outpacing the industry’s efforts to fight it, report finds

The antibiotic pipeline has shrunk 35 percent in five years, falling behind growing antimicrobial resistance worldwide, according to a new report.

Euronews

Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn

UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report finds

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Emma Walmsley’s pay rose almost 50% to £15.6m in final year as GSK boss

Bulk of 2025 renumeration came from share bonuses as drug company’s now former CEO benefitted from stock rise

The Guardian - UK

Patients blame medications for triggering gambling and addictive behaviors, and the numbers are growing

Medication that boost dopamine trigger compulsive and deviant behavior.

We Got This Covered

FTSE 100 Live 19 February: Index slips, Centrica and Rio Tinto lower on results

Centrica shares have fallen sharply after the British Gas owner posted results today.

Evening Standard

GSK, take two: the bullish tone at the top is finally more convincing

New boss Luke Miels knows perils of overpromising but there is growing sense pharma firm is closer to filling potential

The Guardian - UK

FTSE 100 tops 10,400 as Beazley and Entain soar

The FTSE 100 index closed up 87.75 points, 0.9%, at 10,402.34, a new record close.

Evening Standard

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition

The Guardian - UK

GSK posts higher profits but indicates sales growth to slow in 2026

It came amid the first set of results by new chief executive Luke Miels, who took over from Emma Walmsley at the turn of the year.

Evening Standard

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

FTSE 100 Live 04 February: GSK milestone as index soars to new record, AI data jitters continue

GSK results today helped shares surge above 2000p for the first time in over two decades as the FTSE 100 index set a new intraday record.

The Independent UK

GSK to cut roles in overhaul of R&D division

IN FULL

Evening Standard

GSK cutting jobs in UK and US as part of ongoing R&D changes

It is understood around 50 UK jobs so far are being cut in the group’s main UK R&D hub in Stevenage, Hertfordshire.

The Independent UK

Drugs giant to axe up to 350 R&D jobs across the US and UK

About 50 jobs will be impacted in the group’s main UK R&D hub in Stevenage, Hertfordshire

Get all your
news in one place.

100's of premium titles.
One news app.

Evening Standard

Who is on Keir Starmer's China trip, and why are they there?

A delegation of ministers, business leaders and cultural figures are part of the trip, as the Prime Minister seeks to improve relations

The Guardian - UK

GSK to buy food allergy drug maker RAPT in $2.2bn deal

US-based biotech firm is developing treatment for allergies to nuts, milk and eggs in children and adults

Evening Standard

GSK acquiring firm developing food allergy treatment in £1.6bn deal

The transaction is expected to complete during the first quarter of 2026.

Evening Standard

Next impresses as FTSE 100 rockets to fresh high

Next, up 5%, impressed the City with strong Christmas sales.

MarketBeat

Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

The Independent UK

New ‘life-changing’ asthma drug gets green light after rise in hospital admissions

A trial cut hospital admissions by 72 per cent

The Guardian - UK

Revealed: how big businesses are rolling back public support for Pride

Guardian analysis of 20 major companies in UK and US shows mentions of Pride on social media have fallen substantially in past two years

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.